|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer显示文摘AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. RESULTS: Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 mo (range: 3-21 mo), all 6 evaluable patients achieved complete response. Of them, 2 developed localrecurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fi stula. CONCLUSION: Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome. | Shu-Lian Wang Zhongxing Liao Helen Liu( Jaffer Ajani Stephen Swisher James D Cox Ritsuko Komaki | 2006 | World Journal of Gastroenterology2006，12，34： | 27 |
| 2 | An updated review of gastric cancer in the next-generation sequencing era:Insights from bench to bedside and vice versa显示文摘Gastric cancer(GC)is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide.There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs.Recent studies using nextgeneration sequencing(NGS)have revealed a number of potential cancer-driving genes in GC.Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4,a member of the cadherin gene family.Mutations in chromatin remodeling genes(ARID1A,MLL3 and MLL)have been found in 47%of GCs.Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC.Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery,such as DNA methylation,histone modifications,nucleosome positioning,noncoding RNAs and microRNAs.Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings.The antihuman epidermal growth receptor 2(HER2)antibody trastuzumab has led to an era of personalized therapy in GC.In addition,ramucirumab,a monoclonal antibody targeting vascular endothelial growth factor receptor(VEGFR)-2,is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy.Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets,as well as useful biomarkers.In this review,we will summarize the recent advances in the understanding of the molecular pathogenesis of GC,focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets. | Hiroyuki Yamamoto Yoshiyuki Watanabe Tadateru Maehata Ryo Morita Yoshihito Yoshida Ritsuko Oikawa Shinya Ishigooka Shun-ichiro Ozawa Yasumasa Matsuo Kosuke Hosoya Masaki Yamashita Hiroaki Taniguchi Katsuhiko Nosho Hiromu Suzuki Hiroshi Yasuda Yasuhisa Shinomura Fumio Itoh | 2014 | World Journal of Gastroenterology2014，20，14： | 12 |
| 3 | 胸腺瘤放疗的相关定义和报告指南显示文摘放疗在胸腺肿瘤的治疗中仍然占有重要地位,但是很多细节没有明确的定义。例如,如何放疗、如何确定放疗范围、哪些患者需要放疗和如何报告放疗结果都没有统一的标准。ITMIG的成立,给解决这些问题创造了机会。但是先决条件是制定统一的定义和方法,使不同结果能被理解和比较,这也是本文的主旨。文献和形成初步建议,再提交给下一个扩展工作组(Charles hTomas, Lynn Wilson, Gregory Videtic. James Metz, Harun Badakhshi, Clifton Fuller, Franc-oie Mornex, Conrad Falkson, David Ball, and Ken Rosenzweig)审议,之后将建议提交给ITMIG多学科组进一步讨论,形成初稿(包含推荐方法和标准操作流程)后分发给所有ITMIG成员更进一步讨论并反馈意见,最终版本经ITMIG批准并被采用。 | 付浩 中国胸腺瘤协作组全体成员 Daniel Gomez Ritsuko Komaki James Yu Hitoshi Ikushima Andrea Bezjak | 2014 | 中国肺癌杂志2014，17，2： | 6 |
| 4 | 应用最大似然率及随机效应模型探讨非小细胞肺癌放化疗中急性放射性食管炎与照射剂量和疗程的关系显示文摘背景与目的:局部晚期非小细胞肺癌的治疗疗效差,增加治疗强度如同期放化疗是提高疗效的方法,但毒性反应较大。本研究探讨非小细胞肺癌同期放化疗的治疗方式中,应用最大似然率及随机效应模型探讨非小细胞肺癌放化疗中急性放射性食管炎的发生率与照射剂量和疗程时间因素的关系。方法:本研究中的39例病例资料来自于1998年3月-2000年11月间在M.D.Anderson癌症治疗中心进入随机临床Ⅲ期的同期放化疗治疗研究不能手术的Ⅱ期和Ⅲ期非小细胞肺癌患者。所有的患者在放疗前均接受顺铂和口服依托泊苷(VP-16)的化疗。放疗方案为每次1.2Gy,bid,前后野对照治疗至肿瘤剂量达40~50Gy后,采用避开脊髓的斜野放疗至总剂量69.6Gy。病例分布为amifostine治疗组,19例;非amifostine治疗组,20例。还原三维治疗计划设计并计算了剂量-体积直方图(DVHs)。治疗开始后每周对急性放射性食管炎程度评估1次,在放疗结束后1个月再随访评估1次。评分的标准是根据美国放射治疗研究组(RTOG)的急性反应的标准。采用了多因素的随机效应模型及最大似然率的分析以研究在这39例病例中急性放射性食管炎的严重程度与照射剂量和疗程时间因素的关系,并考虑了不同病例个体间的敏感性差异。结果:在amifostine治疗组有11%(2/19),非amifostine治疗组有30%(6/20)的患者发生Ⅲ度的急性食管炎。在这两组中,急性食管炎的发生率在开始治疗后第4周(累计剂量为48Gy)达高峰并呈一稳定状态。随治疗后期剂量的进一步增加,急性食管炎发生的危险性并不明显增加。原因可能是食管粘膜上皮组织的修复和在治疗后的上皮细胞加速再增殖。疗程中的周剂量或累计周剂量要比整个疗程的总剂量更好地预测急性食管炎的发生。结论:肿瘤累积剂量和患者的内在敏感性与Ⅲ度急性放射性食管炎的发生率有关。欲将发生急性食管炎的危险性降低至10%以下,需限制第4周的累计剂量在36Gy以下,或9Gy/周。这可能为开展IMRT等新技术的治疗提供有用的参考信息。 | 章真 Helen Liu Zhongxing Liao Ritsuko Komaki James D Cox | 2006 | 中国癌症杂志2006，16，12： | 5 |
| 5 | Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors显示文摘AIM: To determine the bowel symptoms associated with diabetes and diabetes-related factors after excluding gastrointestinal(GI) organic diseases.METHODS: Participants were 4738(603 diabetic and 4135 non-diabetic) patients who underwent colonoscopy and completed a questionnaire. On the day of pre-colonoscopy, 9 symptoms(borborygmus, abdominal distension, increased flatus, constipation, diarrhea, loose stools, hard stools, fecal urgency, and incomplete evacuation) were prospectively evaluated on a 7-point Likert scale. The test-retest reliability of the bowel symptom scores from the baseline and second questionnaires was analyzed using kappa statistics. Associations between bowel symptom scores and diabetes or diabetes-related factors were analyzed by a rank-ordered logistic model adjusted for related confounders, and odds ratios(ORs) were estimated.RESULTS: In multivariate analysis, constipation [adjusted odds ratio(AOR) = 1.57, CI: 1.33-1.85, P < 0.01] and hard stools(AOR = 1.56, CI: 1.33-1.84, P < 0.01) were associated with diabetes, and fecal urgency(AOR = 1.16, CI: 0.99-1.37, P = 0.07) and incomplete evacuation(AOR = 1.16, CI: 1.00-1.36, P = 0.06) were marginally associated with diabetes. These symptoms remained associated even after excluding organic GI diseases on colonoscopy. Test-retest reliability of symptom score with a mean duration of 3.2 mo was good(mean kappa, 0.69). Associations of symptoms with diabetes-related factors were found; constipation with Hb A1 c ≥ 8.0%(AOR = 2.11, CI: 1.19-3.73), b o d y m a s s i n d e x( B M I) < 2 5( A O R = 2. 1 1, C I : 1.22-3.66), and insulin use(AOR = 1.90, CI: 1.08-3.36); hard stools with diabetes duration(AOR = 1.03, CI: 1.00-1.07); fecal urgency with BMI < 25(AOR = 1.73, CI: 1.00-2.98); and incomplete evacuation with BMI < 25(AOR = 2.60, CI: 1.52-4.43), serum creatinine level(AOR = 1.27, CI: 1.10-1.47), and insulin use(AOR = 1.92, CI: 1.09-3.38).CONCLUSION: Diabetes is associated with constipation, hard stools, fecal urgency, and incomplete evacuation, and poor glycemic control, duration, leanness, and nephropathy affect the risk of these symptoms. | Noriko Ihana-Sugiyama Naoyoshi Nagata Ritsuko Yamamoto-Honda Eiko Izawa Hiroshi Kajio Takuro Shimbo Masafumi Kakei Naomi Uemura Junichi Akiyama Mitsuhiko Noda | 2016 | World Journal of Gastroenterology2016，22，11： | 5 |
| 6 | 非小细胞肺癌术后三维适形放疗与常规放疗的疗效比较显示文摘背景与目的:非小细胞肺癌术后三维适形放疗与常规放疗的疗效比较目前尚缺乏长期随访结果.本研究回顾性分析非小细胞肺癌(NSCLC)术后分别采用三维适形放疗和常规放疗的疗效及放疗反应,比较不同放疗技术对疗效及放疗反应的影响。方法:收集1990年12月-2002年8月美国M.D.安德森癌症研究中心收治的167例Ⅲ.期NSCLC患者的术后放疗资料进行回顾性分析。其中常规放疗组(CV组)90例.三维适形放疗组(CF组)77例。CV组放疗中位剂量为54.3Gy/27次.CF组放疗中位刹龟为53.9Gy/26次.均在5~6周内完成。结果:两组患者病例特征具有可比性。CV组和CF组中位随访时间分别为36个月和24个月,两组无瘤生存率、局部控制率及无远处转移生存率差异无显著性,但两组总生存率差异有显著性(P=0.014)。CF组在肺部纤维化、心脏损伤和血液系统放疔反应发生率显著性上要低于CV组,其余放疗反应差异基本尤最著性。两组死亡原因差异有显著性,CV组有8例患者死于与心脏损伤有关的并发症,而CF组没有。结论:Ⅲ、期NSCLC术后采用改进的三维适形放疗技术不仅可以取得与常规放疗类似的疗效,还可提高总生存率,同时降低了肺部纤维化、心脏损伤和血液系统反应发生率,三维适形放疗的治疗优势值得关注. | 林原 Zhongxing Liao Pamela K.Allen James D.Cox Ritsuko Komaki | 2007 | 中国癌症杂志2007，17，4： | 4 |
| 7 | 应用随机效应模型探讨肺癌放化疗中影响食管炎的剂量和容积因素显示文摘目的 :应用随机效应模型分析非小细胞肺癌同期放化疗中的急性放射性食管炎发生率与食管受到的照射剂量和容积关系。方法 :6 2例不能手术的Ⅱ期和Ⅲ期非小细胞肺癌患者于 1998年 3月至 2 0 0 0年 11月间在M .D .Anderson癌症治疗中心进入随机、临床Ⅲ期的同期放化疗治疗研究 ,比较应用或未用阿米福汀 (amifostine)时对食管毒性反应的作用。对其中 39例有三维治疗计划的病例进行回顾性分析 ,阿米福汀组和非阿米福汀组分别为 19和 2 0例。急性食管炎程度的评估为每周 1次 ,在放疗结束后的 1个月再随访评估 1次。评分的标准根据RTOG急性反应的标准。放疗的方式为 1.2Gy/次 ,2次 /d ,前后野对照治疗至 4 0~ 5 0Gy后采用避开脊髓的斜野放疗 ,至总剂量 6 9.6Gy/ 6周。所有的患者在放疗前均接受顺铂和口服依托泊苷 (VP 16 )的化疗。采用多因素的随机效应模型分析急性食管炎的评分 (严重程度 )与不同的剂量容积因素的关系。结果 :39例中 ,阿米福汀组中 2例(11% ) ,非阿米福汀组 6例 (30 % )患者发生了Ⅲ度的急性食管炎。Ⅲ度急性食管炎最早出现在治疗的第 3周末 ,即累计肿瘤量达 36Gy时。第 4周后 ,呈一平缓的趋势 ,其发生率并不随以后剂量的增加而明显提高。在所有与Ⅲ度食管炎发生有关的剂量和容积因素中 ,以? | 章真 LIU Helen LIAO Zhongxing Ritsuko KOMAKI James DCOX | 2004 | 中国癌症杂志2004，14，6： | 3 |
| 8 | ApoE isoforms,treatment of diabetes and the risk of coronary heart disease显示文摘AIM:To analyze the risk of coronary heart disease in patients with type 2 diabetes mellitus(T2DM)receiving standard medical treatment.METHODS:We performed a retrospective chart analysis of 269 middle-aged patients(age 45-64 years,mean age,53.9±5.5 years)with T2DM and without atherosclerotic cardiovascular events who underwent typing to determine their apolipoprotein E(apoE)isoforms.The apoE isoforms were determined using isoelectric focusing,followed by immunoblotting.We retrospectively evaluated the charts of the 269 patients,recorded between their first visit to the hospital(the study's start point,between 1987 and 1992)and the occurrence of an atherosclerotic cardiovascular event(the study's endpoint)or January 2004,whichever came first.The age-adjusted mean values and the prevalences of covariates were calculated to compare the laboratory data among the apoE phenotypes.To investigate the association of risk factors with the incidence of coronary heart disease during the follow-up period,monovariate and multivariate Cox regression models were used.RESULTS:At enrollment,the mean serum low density lipoprotein(LDL)cholesterol levels were lowest(2.92± 0.89 mmol/L)among the subjects with apoE2(apoE2/2 or apoE2/3)and highest(3.52±0.77 mmol/L)among the subjects with apoE4(apoE3/4 or apoE4/4).No significant differences in mean age or the percentage of smokers were observed among the three groups.Furthermore,no significant differences were observed in the systolic and diastolic blood pressures,body mass index,HbA1c level or serum triglyceride levels among the three groups.There were 47 cases of coronary heart disease over 3285 person-years of follow-up.An age-adjusted multivariate Cox proportional model identified diabetic retinopathy(hazard ratio,2.38,95% CI:1.28-4.43,P=0.006),a high systolic blood pressure(hazard ratio,1.04,95%CI:1.02-1.06,P<0.001) and high HbA1c values(hazard ratio,1.19,95%CI:1.02-1.38,P=0.0029),but not the LDL cholesterol value at enrollment(hazard ratio,1.01,95%CI:0.97-1.05,P=0.77)nor the specific apoE isoform,as significant predictors of coronary heart disease.CONCLUSION:Under standard medical treatment of diabetes,including the control of LDL cholesterol levels,the apoE4 isoform was not associated with coronary heart disease among T2DM patients. | Hideki Ehara Ritsuko Yamamoto-Honda Hiroji Kitazato Yoshihiko Takahashi Shoji Kawazu Yasuo Akanuma Mitsuhiko Noda | 2012 | World Journal of Diabetes2012，3，3： | 3 |
| 9 | Association of primary biliary cirrhosis with idiopathic thrombocytopenic purpura显示文摘Although both primary biliary cirrhosis (PBC) and idiopathic thrombocytopenic purpura (ITP) are autoimmune diseases, the association of the 2 diseases is rare. Here, we report a case of ITP that developed during the follow-up of PBC in a 74-year- old man. The patient had been diagnosed with PBC 12 years previously, and had received treatment with ursodeoxycholic acid. The platelet count decreased from approximately 60 × 109/L to 8 × 109/L, and the association of decompensated liver cirrhosis (PBC) with ITP was diagnosed. Steroid and immune gamma globulin therapy were successful in increasing the platelet count. Interestingly, human leukocyte antigen genotyping detected the alleles DQB10601 and DRB10803, which are related to both PBC and ITP in Japanese patients. This case suggests common immunogenetic factors might be involved in the development of PBC and ITP. | Nobuyuki Toshikuni Ryumei Yamato Haruhiko Kobashi Ken Nishino Nobu Inada Ritsuko Sakanoue Mitsuhiko Suehiro Yoshinori Fujimura Gotaro Yamada | 2008 | World Journal of Gastroenterology2008，14，15： | 2 |
| 10 | Predictors of High-grade Esophagitis After Definitive Three-dimensional Conformal Therapy, Intensity-modulated Radiation Therapy, or Proton Beam Therapy for Non-small cell Lung Cancer显示文摘 | Daniel R. Gomez Susan L. Tucker Mary K. Martel Radhe Mohan Peter A. Balter Jose Luis Lopez Guerra Hongmei Liu Ritsuko Komaki James D. Cox Zhongxing Liao | 2012 | International Journal of Radiation Oncology, Biology, Physics2012，，： | 2 |
| 11 | ⅢA期非小细胞肺癌术后三维适形放疗与常规放疗的初步比较显示文摘目的回顾性比较ⅢA期非小细胞肺癌(NSCLC)术后三维适形放疗(3DCRT组)和常规放疗(CRT组)的近期疗效及放疗反应。方法对美国安德森癌症中心收治的114例ⅢA期NSCLC患者的术后放疗资料进行回顾性分析。CRT组63例,3DCRT组51例。CRT组放疗中位剂量为53.5 Gy分27次,3DCRT组的为52.8 Gy分26次,均在5~6周内完成。结果CRT、3DCRT组中位随访时间分别为28、13个月。两组近期放疗反应、局部控制率及无远处转移生存率等无差异。1、2年总生存率CRT组为80%、62%,3DCRT组为93%、70%。1、2年无瘤生存率CRT组为62%、44%,3DCRT组为58%、32%。两组死亡原因有统计学差异,CRT组有4例死于与心脏损伤有关的并发症,而3DCRT组则无。结论ⅢA期NSCLC术后三维适形放疗可取得与常规放疗类似的近期疗效而并不增加局部复发和远处转移的危险性,对心脏的损伤有降低趋势,对生存率影响则有待更长时间的随访结果。 | 林原 LIAOZhong-xing ALLEN Pamela CHANG Joe COX James KOMAKI Ritsuko | 2006 | 中华放射肿瘤学杂志2006，15，4： | 2 |
| 12 | Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small-Cell Lung Cancer Patient Outcomes显示文摘 | Chad Tang Zhongxing Liao Daniel Gomez Lawrence Levy Yan Zhuang Rediet A. Gebremichael David S. Hong Ritsuko Komaki James W. Welsh | 2014 | International Journal of Radiation Oncology, Biology, Physics2014，，： | 2 |
| 13 | Transmission electron microscopy study of the evolution of precipitates in aged Al–Li–Cu alloys: the θ ′ and T 1 phases显示文摘 | Ritsuko Yoshimura Toyohiko J Konno Eiji Abe Kenji Hiraga | 2003 | Acta Materialia2003，，14： | 2 |
| 14 | Factors Associated with the Clinical Impact of Capsule Endoscopy in Patients with Overt Obscure Gastrointestinal Bleeding显示文摘 | Motohiro Esaki Takayuki Matsumoto Shinichiro Yada Ritsuko Yanaru-Fujisawa Tetsuji Kudo Shunichi Yanai Shotaro Nakamura Mitsuo Iida | 2010 | Digestive Diseases and Sciences2010，，8： | 2 |
| 15 | Technical Advances of Radiation Therapy for Thymic Malignancies显示文摘 | Daniel Gomez Ritsuko Komaki | 2010 | Journal of Thoracic Oncology ( Suppl Mali)2010，，10： | 1 |
| 16 | A Ra pid Eco-Friendly Synthesis of Poly( butylene suecinate) by a Direct Polyesterification under Microwave Irradiation 显示文摘 | Siva Velmathi Ritsuko Nagahata Jun-ichi Sugiyama | 2005 | Macro molecular Rapid Communication2005，26，： | 1 |
| 17 | Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization显示文摘 | Lieben Liesbet Masuyama Ritsuko Torrekens Sophie Van Looveren Riet Schrooten Jan Baatsen Pieter Lafage-Proust Marie-Hélène Dresselaers Tom Feng Jian Q Bonewald Lynda F Meyer Mark B Pike J Wesley Bouillon Roger Carmeliet Geert | 2012 | EN2012，，5： | 1 |
| 18 | Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy显示文摘 | Zhongxing X. Liao Ritsuko R. Komaki Howard D. Thames Helen H. Liu Susan L. Tucker Radhe Mohan Mary K. Martel Xiong Wei Kunyu Yang Edward S. Kim George Blumenschein Waun Ki Hong James D. Cox | 2010 | International Journal of Radiation Oncology Biology Physics2010，，3： | 1 |
| 19 | High-phosphorus diet stimulates receptor activator of nuclear faetor-kB ligand mRNA expression by increasing parathyroid hormone secretion in rats显示文摘 | Shin-ichi Katsumata Ritsuko Masuyama Mariko Uehara | 2005 | British Journal of Nutrition2005，94，： | 1 |
| 20 | Cerehellar dysfunction in progressive supranuclear palsy: a transcranial magnetic stimulation study 显示文摘 | Yuichiro S Masashi H Ritsuko H | 2010 | Mov Disord2010，25，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员